Biochim Biophys Acta Gen Subj. 2018;1862(12):2527–32. https://pubmed.ncbi.nlm.nih.gov/30048742/
8329
Chini EN. Of mice and men: NAD+ boosting with niacin provides hope for mitochondrial myopathy patients. Cell Metab. 2020;31(6):1041–3. https://pubmed.ncbi.nlm.nih.gov/32492387/
8330
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8331
McReynolds MR, Chellappa K, Baur JA. Age-related NAD+ decline. Exp Gerontol. 2020;134:110888. https://pubmed.ncbi.nlm.nih.gov/32097708/
8332
Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2(1):9–31. https://pubmed.ncbi.nlm.nih.gov/32694684/
8333
Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2(1):9–31. https://pubmed.ncbi.nlm.nih.gov/32694684/
8334
Elysium Health. U. S. District Court invalidates Dartmouth patents asserted by ChromaDex. Cision PR Newswire. https://www.prnewswire.com/news-releases/us-district-court-invalidates-dartmouth-patents-asserted-by-chromadex-301381257.html. Published September 21, 2021. Accessed January 28, 2023.; https://www.prnewswire.com/news-releases/us-district-court-invalidates-dartmouth-patents-asserted-by-chromadex-301381257.html
8335
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8336
Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–47. https://pubmed.ncbi.nlm.nih.gov/29514064/
8337
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8338
de Guia RM, Agerholm M, Nielsen TS, et al. Aerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle. Physiol Rep. 2019;7(12):e14139. https://pubmed.ncbi.nlm.nih.gov/31207144/
8339
Zhou CC, Yang X, Hua X, et al. Hepatic NAD+ deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173(15):2352–68. https://pubmed.ncbi.nlm.nih.gov/27174364/
8340
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8341
Koltai E, Szabo Z, Atalay M, et al. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev. 2010;131(1):21–8. https://pubmed.ncbi.nlm.nih.gov/19913571/
8342
Liu LY, Wang F, Zhang XY, et al. Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases. PLoS One. 2012;7(10):e44933. https://pubmed.ncbi.nlm.nih.gov/23071504/
8343
Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature. 2003;423(6936):181–5. https://pubmed.ncbi.nlm.nih.gov/12736687/
8344
Balan V, Miller GS, Kaplun L, et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem. 2008;283(41):27810–9. https://pubmed.ncbi.nlm.nih.gov/18678867/
8345
Yoshida M, Satoh A, Lin JB, et al. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 2019;30(2):329–42.e5. https://pubmed.ncbi.nlm.nih.gov/31204283/
8346
Brouwers B, Stephens NA, Costford SR, et al. Elevated nicotinamide phosphoribosyl transferase in skeletal muscle augments exercise performance and mitochondrial respiratory capacity following exercise training. Front Physiol. 2018;9:704. https://pubmed.ncbi.nlm.nih.gov/29942262/
8347
Costford SR, Brouwers B, Hopf ME, et al. Skeletal muscle overexpression of nicotinamide phosphoribosyl transferase in mice coupled with voluntary exercise augments exercise endurance. Mol Metab. 2018;7:1–11. https://pubmed.ncbi.nlm.nih.gov/29146412/
8348
Frederick DW, Davis JG, Dávila A Jr, et al. Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism. J Biol Chem. 2015;290(3):1546–58. https://pubmed.ncbi.nlm.nih.gov/25411251/
8349
Dollerup OL, Chubanava S, Agerholm M, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J Physiol. 2020;598(4):731–54. https://pubmed.ncbi.nlm.nih.gov/31710095/
8350
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8351
Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010;298(1):E117–26. https://pubmed.ncbi.nlm.nih.gov/19887595/
8352
Lamb DA, Moore JH, Mesquita PHC, et al. Resistance training increases muscle NAD+ and NADH concentrations as well as NAMPT protein levels and global sirtuin activity in middle-aged, overweight, untrained individuals. Aging (Albany NY). 2020;12(10):9447–60. https://pubmed.ncbi.nlm.nih.gov/32369778/
8353
Ruan Q, Ruan J, Zhang W, Qian F, Yu Z. Targeting NAD+ degradation: the therapeutic potential of flavonoids for Alzheimer’s disease and cognitive frailty. Pharmacol Res. 2018;128:345–58. https://pubmed.ncbi.nlm.nih.gov/28847709/
8354
Soma M, Lalam SK. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Mol Biol Rep. 2022;49(10):9737–48. https://pubmed.ncbi.nlm.nih.gov/35441939/
8355
Skidmore CJ, Davies MI, Goodwin PM, et al. The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by ¿-radiation and N-methyl-N-nitrosourea. Eur J Biochem. 1979;101(1):135–42. https://pubmed.ncbi.nlm.nih.gov/228934/
8356
Pacher P, Szabó C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25(3):235–60. https://pubmed.ncbi.nlm.nih.gov/17919258/
8357
Palmer RD, Vaccarezza M. Nicotinamide adenine dinucleotide and the sirtuins caution: pro-cancer functions. Aging Med (Milton). 2021;4(4):337–44. https://pubmed.ncbi.nlm.nih.gov/34964015/
8358
Amici SA, Young NA, Narvaez-Miranda J, et al. CD38 is robustly induced in human macrophages and monocytes in inflammatory conditions. Front Immunol. 2018;9:1593. https://pubmed.ncbi.nlm.nih.gov/30042766/
8359
Polzonetti V, Carpi FM, Micozzi D, Pucciarelli S, Vincenzetti S, Napolioni V. Population variability in CD38 activity: correlation with age and significant effect of TNF-a-308GA and CD38 184CG SNPs. Mol Genet Metab. 2012;105(3):502–7. https://pubmed.ncbi.nlm.nih.gov/22236458/
8360
Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. https://pubmed.ncbi.nlm.nih.gov/35134387/
8361
Wu S, Zhang R. CD38-expressing macrophages drive age-related NAD+ decline. Nat Metab. 2020;2(11):1186–7. https://pubmed.ncbi.nlm.nih.gov/33199923/
8362
Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates
